cabazitaxel + lapatinib
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Breast Cancer With Intracranial Metastases
Conditions
Metastatic Breast Cancer With Intracranial Metastases
Trial Timeline
May 1, 2014 → Apr 1, 2017
NCT ID
NCT01934894About cabazitaxel + lapatinib
cabazitaxel + lapatinib is a phase 2 stage product being developed by Novartis for Metastatic Breast Cancer With Intracranial Metastases. The current trial status is terminated. This product is registered under clinical trial identifier NCT01934894. Target conditions include Metastatic Breast Cancer With Intracranial Metastases.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01934894 | Phase 2 | Terminated |
Competing Products
20 competing products in Metastatic Breast Cancer With Intracranial Metastases